mRNA Display Reaches for the Clinic with New PCSK9 Inhibitor
Sabrina E. Iskandar, Albert A. Bowers
Abstract
Merck & Co. recently reported one of the first mRNA display-derived clinical candidates in a bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Herein, we discuss the chemical and pharmacological challenges surmounted in bringing this compound to trials and the current outlook for mRNA display-based therapeutic development.
Topics & Concepts
KexinPCSK9Proprotein convertaseSubtilisinClinical trialMessenger RNAMedicinePharmacologyBioinformaticsChemistryInternal medicineLDL receptorBiologyBiochemistryGeneEnzymeCholesterolLipoproteinRNA Research and SplicingLipoproteins and Cardiovascular HealthClick Chemistry and Applications